Abstract
Extreme environments are mainly occupied by Archaea that contain in their cytoplasmic membrane unique mono- and bi-polar ether lipids that exhibit extraordinary resistance towards chemical and/or enzymatic degradation, over a wide range of pH values, extreme temperatures, and high salt concentrations. The archaeal core lipid structures show considerable variation within the various subgroups of the Archaea, but there are groupings of structural types that can be associated with the three principal archaeal phenotypes. These unusual lipids play a key role in the adaptation of the halophilic, methanogenic, (hyper)thermophilic/thermoacidophilic Archaea to extreme habitats by optimizing membrane composition and properties in direct response to the growth conditions of the organisms. The uniqueness of archaeal lipid structures and functions within membranes has prompted a great deal of interest in the use of natural lipids or synthetic analogues as innovative materials for the development of biotechnological applications. In this review, recent uses of diether-type and tetraether-type lipids as nanocarriers in the drug delivery field are discussed, with special attention to the promising oral/topical administration routes.
Keywords: Archaeal lipids, archaeosome, extremophile, nanocarriers, oral/topical drug delivery, vaccine.
Current Biotechnology
Title:Applications of Extremophilic Archaeal Lipids in the Field of Nanocarriers for Oral/Topical Drug Delivery
Volume: 2 Issue: 4
Author(s): Thierry Benvegnu, Loïc Lemiègre, Sylvain Dalençon and Jelena Jeftić
Affiliation:
Keywords: Archaeal lipids, archaeosome, extremophile, nanocarriers, oral/topical drug delivery, vaccine.
Abstract: Extreme environments are mainly occupied by Archaea that contain in their cytoplasmic membrane unique mono- and bi-polar ether lipids that exhibit extraordinary resistance towards chemical and/or enzymatic degradation, over a wide range of pH values, extreme temperatures, and high salt concentrations. The archaeal core lipid structures show considerable variation within the various subgroups of the Archaea, but there are groupings of structural types that can be associated with the three principal archaeal phenotypes. These unusual lipids play a key role in the adaptation of the halophilic, methanogenic, (hyper)thermophilic/thermoacidophilic Archaea to extreme habitats by optimizing membrane composition and properties in direct response to the growth conditions of the organisms. The uniqueness of archaeal lipid structures and functions within membranes has prompted a great deal of interest in the use of natural lipids or synthetic analogues as innovative materials for the development of biotechnological applications. In this review, recent uses of diether-type and tetraether-type lipids as nanocarriers in the drug delivery field are discussed, with special attention to the promising oral/topical administration routes.
Export Options
About this article
Cite this article as:
Benvegnu Thierry, Lemiègre Loïc, Dalençon Sylvain and Jeftić Jelena, Applications of Extremophilic Archaeal Lipids in the Field of Nanocarriers for Oral/Topical Drug Delivery, Current Biotechnology 2013; 2 (4) . https://dx.doi.org/10.2174/18722083113076660026
DOI https://dx.doi.org/10.2174/18722083113076660026 |
Print ISSN 2211-5501 |
Publisher Name Bentham Science Publisher |
Online ISSN 2211-551X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Mechanisms of the Penetration of Blood-Borne Substances into the Brain
Current Neuropharmacology Which Dose of Folic Acid Should Pregnant Diabetic Women Receive?
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Anti-Atherogenic Role of Peroxisome Proliferator-Activated Receptor Ligands
Current Cardiology Reviews Serum Alpha-fetoprotein Levels and Response to Direct Antiviral Therapy in Patients with Chronic Hepatitis C: Real-world Results from 1716 Patients in Egypt
Endocrine, Metabolic & Immune Disorders - Drug Targets New Aspects of Statin Safety
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Thiopurine Methyltransferase Genetic Polymorphisms and Activity and Metabolic Products of Azathioprine in Patients with Inflammatory Bowel Disease
Endocrine, Metabolic & Immune Disorders - Drug Targets Changes in the Apoptotic and Survival Signaling in Cancer Cells and Their Potential Therapeutic Implications
Current Cancer Drug Targets Editorial[Hot topic: Targets of Metabolic Toxicity of HIV Antiretroviral Drugs: The Multiple Roads to Lipodystrophy and Metabolic Syndrome (Executive Editors: Pere Domingo and Francesc Villarroya)]
Current Pharmaceutical Design Editorial [Hot Topic:Neurodegenerative Disorders: From Molecules to Man (Part 1) (Guest Editors: Giuseppe Di Giovanni, Vincenzo Di Matteo and Ennio Esposito)]
CNS & Neurological Disorders - Drug Targets Endothelial Progenitor Cells and Vascular Biology in Diabetes Mellitus: Current Knowledge and Future Perspectives
Current Diabetes Reviews The Role of Matrix Metalloproteinases in Diabetes Mellitus
Current Topics in Medicinal Chemistry Microglia Phenotype Diversity
CNS & Neurological Disorders - Drug Targets A Multicenter Study of IgE Sensitization to <i>Anisakis simplex</i> and Diet Recommendations
Endocrine, Metabolic & Immune Disorders - Drug Targets Hyperglycemia Regulates TXNIP/TRX/ROS Axis via p38 MAPK and ERK Pathways in Pancreatic Cancer
Current Cancer Drug Targets Obesity and Body Composition in Man and Woman: Associated Diseases and the New Role of Gut Microbiota
Current Medicinal Chemistry Autophagy to the Rescue
Current Neurovascular Research Nucleic Acid-based Technologies in Therapy of Malignant Gliomas
Current Pharmaceutical Biotechnology C75, a Fatty Acid Synthase (FAS) Inhibitor
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) IRS-1 pY612 and Akt-1/PKB pT308 Phosphorylation and Antiinflammatory Effect of Diindolylmethane in Adipocytes Cocultured with Macrophages
Medicinal Chemistry Editorial [Hot Topic: Vasoactive Intestinal Peptide (VIP): Historic Perspective and Future Potential]
Endocrine, Metabolic & Immune Disorders - Drug Targets